Hans F. Schmitthenner

Hans F. Schmitthenner

Auto-generated profile, based on publicly available information

Hans F. Schmitthenner

School of Chemistry and Materials Science Rochester Institute of Technology Rochester NY 14623 USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Theranostics
Verified
Journal Article
Open access
JYJiang Yang
Jiang Yang
CZChunhua Zhao
Chunhua Zhao
JLJacky Lim
Jacky Lim
LZLina Zhao
Lina Zhao
RTRyan Le Tourneau
Ryan Le Tourneau
HSHans Schmitthenner
Hans Schmitthenner
Rationale: Most contemporary cancer therapeutic paradigms involve initial imaging as a treatment roadmap, followed by the active engagement of surgical operations. Current approved intraoperative contrast agents exemplified by indocyanine green (ICG) have a few drawbacks including the inability of pre-surgical localization. Alternative near-infrared (NIR) dyes including IRDye800cw are being explored in advanced clinical trials but often encounter low chemical yields and complex purifications owing to the asymmetric synthesis. A single contrast agent with ease of synthesis that works in multiple cancer types and simultaneously allows presurgical imaging, intraoperative deep-tissue three-dimensional visualization, and high-speed microscopic visualization of tumor margins via spatiotemporally complementary modalities would be beneficial.

1 June 2016 in Journal of Biomedical Optics
Verified
Journal Article
Open access
PDF file
VDVikram Dogra
Vikram Dogra
BCBhargava Chinni
Bhargava Chinni
SSShalini Singh
Shalini Singh
HSHans Schmitthenner
Hans Schmitthenner
NRNavalgund Rao
Navalgund Rao
KNKent L. Nastiuk
Kent L. Nastiuk
The clinical management of early stage, organ-confined prostate cancer (PrCa) is challenging. The introduction of serum prostate-specific antigen (PSA) screening in the 1980s led to a spike in the apparent incidence of PrCa, due to the detection of previously underdiagnosed indolent cancers, which grow slowly and do not affect lifespan.1 While PSA screening has declined from its peak, most PrCa is still screen-detected and, therefore, likely to be indolent, requiring no treatment. Unfortunately, there is no reliable technology to identify the rare aggressive cancers among the mass of indolent screen-detected PrCa, which has led to frequent overtreatment by surgery or radiation. A lot of effort has been focused on the development of tissue or serum biomarkers to differentiate indolent from aggressive disease, but this has not yet yielded sensitive and specific clinical tools. Consequently, the current clinical paradigm for screen-detected PrCa is active surveillance2,3 (AS): monitoring by serum PSA testing and serial prostate biopsies to determine the grade (Gleason score) and extent of tumor.

4 June 2021 in ACS Applied Bio Materials
Verified
Journal Article
Closed access
HSHans F. Schmitthenner
Hans F. Schmitthenner
TBTaylor M. Barrett
Taylor M. Barrett
SBStephanie A. Beach
Stephanie A. Beach
LHLauren E. Heese
Lauren E. Heese
CWChelsea Weidman
Chelsea Weidman
MFMaureen C. Ferran
Maureen C. Ferran

4 December 2019 in Photochemical & Photobiological Sciences
Verified
Journal Article
Closed access
PDF file
DDDamien E. Dobson
Damien E. Dobson
EMEmily R. Mahoney
Emily R. Mahoney
TMToan P. Mach
Toan P. Mach
RLRyan J. LeTourneau
Ryan J. LeTourneau
HSHans F. Schmitthenner
Hans F. Schmitthenner
A series of Cy5.5 dye analogs and targeted probes with net charges varied from −3 to 0 were synthesized by an optimized method, followed by comparing their spectral and photostability properties in saturated solutions of air, oxygen, and argon. The Cy5.5 analogs with reduced charge were relatively stable when irridated at their excitation maxima, with a trend of higher stability with lower net charge states. The photostability of dyes was markedly lower in pure oxygen and higher in inert argon relative to ambient atmospheric conditions. The stability of c(RGDyK) conjugates as models of targeted molecular imaging agents mirrored these results and demonstrated the practical utility of the new family of Cy5.5 fluorophores.

24 September 2019 in Chemistry – A European Journal
Verified
Journal Article
Closed access
HSHans F. Schmitthenner
Hans F. Schmitthenner
DDDamien E. Dobson
Damien E. Dobson
KJKelsea G. Jones
Kelsea G. Jones
NANnamdi Akporji
Nnamdi Akporji
DSDana Q. M. Soika
Dana Q. M. Soika
Joseph P. HornakJoseph P. Hornak
Joseph P. Hornak

19 July 2024 in ChemMedChem
Verified
Journal Article
Closed access
AOAndrew M. O'BRien
Andrew M. O'BRien
GPGriffin C. Pileski
Griffin C. Pileski
MHMatthew P. Henry
Matthew P. Henry
DSDana Q. M. Soika
Dana Q. M. Soika
ADAlex W. Deutsch
Alex W. Deutsch
HSHans F. Schmitthenner
Hans F. Schmitthenner